Core Viewpoint - China Medical System Holdings Limited's subsidiary, Dermavon Holdings Limited, has received acceptance from the National Medical Products Administration of China for the New Drug Application of ruxolitinib phosphate cream for treating mild to moderate atopic dermatitis, which is expected to accelerate the marketing approval process [1][4]. Group 1: Product Development and Approval - Ruxolitinib phosphate cream has been approved for marketing by the NMPA for the treatment of vitiligo and is now expanding its indications to atopic dermatitis, marking a significant milestone in its therapeutic applications [2]. - The NDA for ruxolitinib phosphate cream has been included in the Priority Review List, reducing the review timeline from 200 days to 130 days, which is anticipated to expedite the product's availability to patients [4]. Group 2: Clinical Trial Results - The product demonstrated robust efficacy in a Phase III clinical trial, achieving a significantly higher proportion of subjects reaching an Investigator's Global Assessment score of 0 or 1 compared to placebo (63.0% vs 9.2%, P < 0.001) [6]. - For the secondary endpoint, 78.0% of subjects treated with ruxolitinib phosphate cream achieved at least a 75% improvement in the Eczema Area and Severity Index score compared to 15.4% in the placebo group (P < 0.001) [6]. Group 3: Market Potential and Strategic Positioning - Atopic dermatitis affects over 54 million patients in China, with mild to moderate cases accounting for 98% of these, indicating a substantial market opportunity for ruxolitinib phosphate cream [5]. - Dermavon is developing a comprehensive "treatment + care" solution for atopic dermatitis, which includes ruxolitinib phosphate cream and other therapeutic options, enhancing its leadership in dermatology [6][7]. - The acceptance of the NDA for atopic dermatitis is expected to strengthen Dermavon's strategic positioning in skin treatments and create synergies with its existing product portfolio, potentially enhancing market competitiveness [8].

Core Viewpoint - China Medical System Holdings Limited's subsidiary, Dermavon Holdings Limited, received approval for ruxolitinib phosphate cream, the first targeted drug for non-segmental vitiligo in China, addressing a significant unmet clinical need for over 10 million patients [1][4]. Group 1: Product Approval and Market Potential - Ruxolitinib phosphate cream is the first drug approved by both the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo [2]. - The product has been prescribed to over 7,000 patients at Boao Super Hospital and is available in more than twenty hospitals across major cities in China, indicating strong clinical demand [2]. - The approval is expected to enhance Dermavon's product portfolio in skin treatment, potentially synergizing with existing products like ILUMETRI and Hirudoid [4]. Group 2: Clinical Efficacy and Safety - In overseas Phase III clinical studies, 29.9% of patients achieved at least 75% improvement in the Facial Vitiligo Area Score Index after 24 weeks of treatment, compared to 7.5% and 12.9% in placebo groups [3]. - Real-world studies in China showed consistent positive efficacy with no new safety events reported, indicating a favorable safety profile for the product [3]. Group 3: Future Developments - The Phase III clinical trial for ruxolitinib phosphate cream in treating mild to moderate atopic dermatitis has also shown positive results, with an NDA actively being pursued for this indication [5]. - The approval of ruxolitinib phosphate cream fills a significant gap in targeted treatment options for vitiligo, which affects approximately 10.3 million patients in China [6].

Core Viewpoint - China Medical System Holdings Limited's subsidiary, Dermavon Holdings Limited, has obtained licensing rights for the innovative oral JAK1 inhibitor povorcitinib, which is aimed at treating non-segmental vitiligo and has been recognized as a Breakthrough Therapeutic Drug by the NMPA, potentially expediting its development and review process in China [1][6]. Group 1: Product Development and Clinical Trials - Povorcitinib is currently undergoing Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa, and prurigo nodularis in various countries outside China, with a Phase 2 trial for asthma also in progress [2]. - In March 2023, Incyte reported that povorcitinib met the primary endpoint in a global Phase 2b trial for non-segmental vitiligo, showing significant improvement in total body repigmentation after 24 weeks of treatment [3]. - Dermavon received approval from the NMPA in August 2025 to conduct clinical trials for povorcitinib in China, with plans to explore additional indications for skin-related diseases in the future [4]. Group 2: Market Potential and Patient Impact - Vitiligo affects approximately 10.3 million patients in China, with around 8.2 million suffering from non-segmental vitiligo, highlighting a significant unmet medical need for effective treatments [5]. - If approved, povorcitinib could offer a differentiated treatment option for non-segmental vitiligo patients, particularly those with moderate to severe forms of the disease [5]. - The inclusion of povorcitinib in the Breakthrough Therapeutic Drugs list is expected to enhance its clinical and commercial value, potentially benefiting patients with skin diseases through synergy with other Dermavon products [6]. Group 3: Collaboration and Licensing - Dermavon entered into a Collaboration and License Agreement with Incyte on March 31, 2024, granting exclusive rights to develop and commercialize povorcitinib in several regions, including Mainland China and Southeast Asia [7].